相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents
Shuku Sato et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma
Jing Liu et al.
NATURE COMMUNICATIONS (2021)
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma
Ying Xie et al.
ONCOGENE (2020)
Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis
Qin Tang et al.
CELL PROLIFERATION (2020)
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis
Qianqian Wang et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia
Joanna Pierro et al.
MOLECULAR CANCER RESEARCH (2020)
HRP2-DPF3a-BAF complex coordinates histone modification and chromatin remodeling to regulate myogenic gene transcription
Xu Zhu et al.
NUCLEIC ACIDS RESEARCH (2020)
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
Nadine Abdallah et al.
BLOOD CANCER JOURNAL (2020)
Mdig promotes oncogenic gene expression through antagonizing repressive histone methylation markers
Qian Zhang et al.
THERANOSTICS (2020)
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma
Chao He et al.
CELL DEATH & DISEASE (2019)
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Benjamin G. Barwick et al.
NATURE COMMUNICATIONS (2019)
Understanding histone H3 lysine 36 methylation and its deregulation in disease
Jie Li et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
Lai Wei et al.
NATURE COMMUNICATIONS (2019)
NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains
Priscillia Lhoumaud et al.
NATURE COMMUNICATIONS (2019)
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2019)
LEDGF and HDGF2 relieve the nucleosome-induced barrier to transcription in differentiated cells
Gary LeRoy et al.
SCIENCE ADVANCES (2019)
CRISPR/Cas9 library screening for drug target discovery
Morito Kurata et al.
JOURNAL OF HUMAN GENETICS (2018)
Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS
Nasrin Rastgoo et al.
LEUKEMIA (2018)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
P. Musto et al.
ANNALS OF ONCOLOGY (2017)
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer
Michiko Kodama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy
Leyuan Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Ola Rizq et al.
CLINICAL CANCER RESEARCH (2017)
Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination
Annika Baude et al.
NUCLEIC ACIDS RESEARCH (2016)
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes
Junjian Wang et al.
CANCER LETTERS (2016)
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents
M. Y. Shah et al.
ONCOGENE (2016)
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma
Huan Liu et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
HDGF-related protein-2 (HRP-2) acts as an oncogene to promote cell growth in hepatocellular carcinoma
Kun Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance
Zhiqiang Liu et al.
BLOOD (2014)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor
Hao Wang et al.
NUCLEIC ACIDS RESEARCH (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation
Wen Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Fenghuang Zhan et al.
BLOOD (2008)
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
David Gonzalez et al.
BLOOD (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark
Alexander J. Ruthenburg et al.
MOLECULAR CELL (2007)
Reading protein modifications with interaction domains
Bruce T. Seet et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance
W Jaksic et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
分享论文
